In Vivo Eval - Combo Therapy for Anticancer Activity

Eiseman, Julie L.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: Division of Cancer Treatment (NCI)
• Type: Research and Development Contracts (N01)
• Project #: N01CM027752-002
• Application #: 3610311
• Project Start: 1992-07-01
• Project End: 1994-11-30
• Budget Start: 1993-06-11
• Budget End: 1994-03-31
• Fiscal Year: 1993

Institution

• Name: University of Maryland Baltimore
• Type: Schools of Medicine
• DUNS #: 003255213
• City: Baltimore
• State: MD
• Country: United States
• Zip Code: 21201

Publications

Florian Jr, Jeffry A; Eiseman, Julie L; Parker, Robert S (2008) Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model. Comput Biol Med 38:339-47

Florian Jr, J A; Eiseman, J L; Parker, R S (2005) Accounting for quiescent cells in tumour growth and cancer treatment. Syst Biol (Stevenage) 152:185-92

Conley, B A; Ramsland, T S; Sentz, D L et al. (1999) Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother Pharmacol 43:183-97